Research News
A phase 2 trial showed cendakimab, an IL-13 inhibitor, reduced Eczema Area and Severity Index scores in moderate to severe atopic dermatitis patients.
Newswise — Rosacea, a common and disabling skin condition, affects 10 percent of the population worldwide. Symptoms of the chronic inflammatory skin disease may be persistent, and triggered by daily exposures like sun and heat.